Orgenesis IncNASDAQ:ORGSNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4602
- TODAY'S CHANGE (%)-0.0198 (-4.1250%)
- Bid / Lots0.4601/ 15
- Ask / Lots0.4999/ 7
- Open / Previous Close0.4750 / 0.4800
- Day Range
- 52 Week Range
- Volume17,038
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ORGS |
|---|---|---|
| 09:32 ET | 6308 | 0.475 |
| 09:43 ET | 442 | 0.45 |
| 09:54 ET | 180 | 0.451178 |
| 09:57 ET | 800 | 0.46985 |
| 10:10 ET | 100 | 0.479571 |
| 10:15 ET | 1103 | 0.46 |
| 10:55 ET | 100 | 0.461 |
| 11:36 ET | 200 | 0.4601 |
| 11:58 ET | 3700 | 0.4609 |
| 12:52 ET | 100 | 0.4602 |
| 01:33 ET | 231 | 0.4601 |
| 02:42 ET | 775 | 0.4601 |
| 02:49 ET | 400 | 0.4602 |
| 02:51 ET | 100 | 0.4602 |
| 03:02 ET | 100 | 0.4602 |
| 03:20 ET | 400 | 0.4602 |
May 21, 2024
Orgenesis Provides Business Update for the First Quarter of 2024, from 7:00AM ET on Tuesday May 21, 2024 by Dow Jones
7:00AM ET on Tuesday May 21, 2024 by Dow JonesPress Release: Orgenesis Provides Business Update for the First Quarter of 2024, from 7:00AM ET on Tuesday May 21, 2024 by Dow Jones
7:00AM ET on Tuesday May 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Orgenesis Inc | 16.5M | -0.3x | --- |
Innovative Eyewear Inc | 17.2M | -0.7x | --- |
Agape ATP Corp | 21.4M | -8.8x | --- |
Neuraxis Inc | 21.0M | -0.9x | --- |
PetVivo Holdings Inc | 10.4M | -0.8x | --- |
Citrine Global Corp | 9.7M | -4.0x | --- |
Company Information
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Contact Information
- Headquarters
- 20271 Goldenrod LaneGERMANTOWN, MD, United States 20876
- Phone
- 480-659-6404
- Fax
- ---
Executives
- Chairperson of the Board of Directors, Chief Executive Officer
- Vered Caplan
- Chief Financial Officer
- Victor Miller
- Independent Director
- Yaron Adler
- Independent Director
- Ashish Nanda
- Independent Director
- Mario Philips
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.5M |
|---|---|
Revenue (TTM) | $529.0K |
Shares Outstanding | 34.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.19 |
EPS | $-1.53 |
Book Value | $-0.66 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 31.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -9,172.21% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
